Literature DB >> 984786

Comparative pharmacology of josamycin and erythromycin stearate.

L J Strausbaugh, W K Bolton, J A Dilworth, R L Guerrant, M A Sande.   

Abstract

Two macrolide antibiotics, josamycin and erythromycin stearate, were administered orally to healthy, adult male volunteers for a comparative study of their pharmacological properties. In comparable doses, josamycin and erythromycin produced similar plasma concentrations, with similar half-lives and elimination constants. An initial loading dose of 1.5 g of josamycin produced greater peak concentrations of antibiotic throughout a 10-day period with a regimen of every 6 h. In addition, josamycin tended to reach higher peak and trough concentrations after regimens of every 6 or 8 h were maintained for 2 days. Josamycin penetrated into saliva, sweat, and tears, and it was better tolerated in fasting subjects than was erythromycin stearate.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984786      PMCID: PMC429769          DOI: 10.1128/AAC.10.3.450

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  In vitro susceptibility studies with josamycin and erythromycin.

Authors:  L J Strausbaugh; J A Dilworth; J M Gwaltney; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

2.  A CLINICAL STUDY OF ERYTHROMYCIN: A COMPARATIVE EVALUATION OF SEVERAL SALTS.

Authors:  B W BILLOW; E A THOMPSON; A STERN; A FLORIO
Journal:  Curr Ther Res Clin Exp       Date:  1964-05

3.  Prediction of antimeningococcic chemoprophylactic efficacy.

Authors:  P D Hoeprich
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

4.  Proposed model for screening antimicrobial agents for potential use in eliminating meningococci from the nasopharynx of healthy carriers.

Authors:  L F Devine; R C Knowles; W E Pierce; R O Peckinpaugh; C R Hagerman; R I Lytle
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968
  4 in total
  8 in total

1.  In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae.

Authors:  J W Biddle; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

5.  Absorption of orally administered nafcillin in normal healthy volunteers.

Authors:  C Watanakunakorn
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

6.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

7.  Josamycin-induced pedal oedema.

Authors:  X Bosch; E Pedrol; X Casado; A Urbano-Marquez
Journal:  BMJ       Date:  1993-07-03

8.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.